Literature DB >> 11823052

MplK, a natural variant of the thrombopoietin receptor with a truncated cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell growth.

Gaël A Millot1, Fréderic Feger, Loic Garçon, William Vainchenker, Dominique Dumenil, Fédor Svinarchuk.   

Abstract

OBJECTIVE: Interaction of thrombopoietin (TPO) with its receptor c-Mpl is responsible for the formation of megakaryocytes and platelets. In humans, there are two major c-mpl molecules, MplP and MplK, which are generated by alternative splicing. In contrast to MplP, MplK has none of the intracellular sequences required for typical signal transduction but instead has a unique 27 amino acid sequence that is coded by intron 10. We tested to determine if MplK exerts a negative effect on TPO Mpl signal transduction by interfering with the normal homodimerization of MplP.
MATERIALS AND METHODS: A cassette coding for MplK cDNA was introduced into parental and MplP-expressing BaF3 cells and TPO-mediated cell growth studied.
RESULTS: Cells expressing MplK alone did not respond to TPO compared to cells that expressed MplP. When MplK was coexpressed with MplP on the cell surface of BaF3, no modification in cell growth was observed when compared to those expressing MplP alone. To determine if the normal homodimerization process was negatively influenced, two genetically engineered variants of c-Mpl, one lacking the box1 sequence and the other containing only the first nine amino acids of the intracellular domain, were introduced into MplP-expressing cells. In contrast to MplK, these mutants had a dominant negative effect on TPO-mediated cell growth.
CONCLUSIONS: MplK does not influence TPO-mediated growth of Mpl-expressing cells. Our data suggest that the absence of a dominant negative effect of MplK most probably is due to the inability of MplK to dimerize with the MplP receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823052     DOI: 10.1016/s0301-472x(01)00776-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

Review 1.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl.

Authors:  Nan Xiao; Suparna Laha; Shankar P Das; Kayla Morlock; Jonathan L Jesneck; Glen D Raffel
Journal:  Blood       Date:  2014-12-02       Impact factor: 22.113

3.  Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation.

Authors:  Zahra Kadri; Leila Maouche-Chretien; Heather M Rooke; Stuart H Orkin; Paul-Henri Romeo; Patrick Mayeux; Philippe Leboulch; Stany Chretien
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance.

Authors:  Fei Li; Yuanyan Xiong; Mo Yang; Peiling Chen; Jingkai Zhang; Qiong Wang; Miao Xu; Yiming Wang; Zuyong He; Xin Zhao; Junyu Huang; Xiaoqiong Gu; Li Zhang; Rui Sun; Xunsha Sun; Jingyao Li; Jinxin Ou; Ting Xu; Xueying Huang; Yange Cao; Xiaohong Ruby Xu; Danielle Karakas; June Li; Heyu Ni; Qing Zhang
Journal:  Cell Death Dis       Date:  2022-10-13       Impact factor: 9.685

5.  Micro-concentration Lipopolysaccharide as a Novel Stimulator of Megakaryocytopoiesis that Synergizes with IL-6 for Platelet Production.

Authors:  Di Wu; Jun Xie; Xuejun Wang; Bingcheng Zou; Yin Yu; Tao Jing; Songmei Zhang; Qing Zhang
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.